0000950170-23-031788.txt : 20230705
0000950170-23-031788.hdr.sgml : 20230705
20230705174350
ACCESSION NUMBER: 0000950170-23-031788
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230630
FILED AS OF DATE: 20230705
DATE AS OF CHANGE: 20230705
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Phillips Gary M.
CENTRAL INDEX KEY: 0001197795
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36332
FILM NUMBER: 231070968
MAIL ADDRESS:
STREET 1: 675 MCDONNELL BLVD.
CITY: HAZELWOOD
STATE: MO
ZIP: 63042
FORMER NAME:
FORMER CONFORMED NAME: PHILLIPS GARY M
DATE OF NAME CHANGE: 20021010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc.
CENTRAL INDEX KEY: 0001341235
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-761-4904
MAIL ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: Aldexa Therapeutics, Inc.
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Neuron Systems Inc
DATE OF NAME CHANGE: 20051012
4
1
ownership.xml
4
X0407
4
2023-06-30
0001341235
Aldeyra Therapeutics, Inc.
ALDX
0001197795
Phillips Gary M.
C/O ALDEYRA THERAPEUTICS, INC.
131 HARTWELL AVENUE
LEXINGTON
MA
02421
true
false
false
false
false
Stock Option (Right to Buy)
8.39
2023-06-30
4
A
false
21222
0.00
A
2033-06-29
Common Stock
21222
21222
D
Stock Option (Right to Buy)
8.39
2023-06-30
4
A
false
1829
0.00
A
2033-06-29
Common Stock
1829
1829
D
Stock Option (Right to Buy)
8.39
2023-06-30
4
A
false
1372
0.00
A
2033-06-29
Common Stock
1372
1372
D
Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date.
Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.
/s/ Gary Phillips
2023-07-05